Atom Investors’s Adicet Bio ACET Stock Holding History

Atom Investors’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-16,207	Closed	-$609K	–	462
2024 Q1	$609K	Buy	+16,207	New	+$670K	0.08%	304
2022 Q3	–	Sell	-736	Closed	-$172K	–	276
2022 Q2	$172K	Buy	+736	New	+$162K	0.08%	193

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Atom Investors's ACET Position: Q2 2024 in Review

Atom Investors sold out of Adicet Bio (ACET) in Q2 2024, closing a stake of 16,207 shares — an estimated $609K sold.

Atom Investors first reported a position in ACET in Q2 2022 and held it in 2 quarters. The position peaked at $609K in Q1 2024. 86 funds tracked by Wall St. Rank hold ACET as of Q2 2024.

Atom Investors reported no remaining Adicet Bio position as of Q2 2024 after selling out during the quarter.
Atom Investors sold 16,207 Adicet Bio shares in Q2 2024, an estimated $609K.
Atom Investors first reported a position in Adicet Bio in Q2 2022 and held it in 2 quarters.
Atom Investors's Adicet Bio position peaked at $609K in Q1 2024.
86 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2024.

Based on Atom Investors's 13F filing for Q2 2024, filed 14 Aug 2024.